Tarveda Therapeutics Overview
- Year Founded
-
2011
- Status
-
Out of Business
- Employees
-
6
- Latest Deal Type
-
Liquidation
Tarveda Therapeutics General Information
Description
Developer of pentarin miniature drug conjugate medicines intended to make a difference in the treatment of patients with solid tumor malignancies. The company's platform provides a lead drug candidate that releases its potent topoisomerase 1 inhibitor payload, SN38 and it also develops a miniature drug conjugate in clinical evaluation for the treatment of patients with somatostatin receptor 2 expressing neuroendocrine, small cell lung, and other solid tumors, enabling companies to extend the lives of patients with hard to treat cancers while minimizing potential toxicities.
Contact Information
Website
www.tarvedatx.comCorporate Office
- 134 Coolidge Avenue
- Watertown, MA 02472
- United States
Corporate Office
- 134 Coolidge Avenue
- Watertown, MA 02472
- United States
Tarveda Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Bankruptcy: Liquidation | 07-Apr-2022 | Completed | Bankruptcy: Liquidation | |||
| 11. Later Stage VC | 27-Sep-2021 | Completed | Clinical Trials - Phase 2 | |||
| 10. Secondary Transaction - Private | 01-Mar-2021 | Completed | Clinical Trials - Phase 2 | |||
| 9. Later Stage VC (Series 2) | 28-Dec-2020 | Completed | Clinical Trials - Phase 2 | |||
| 8. Reverse Merger | 07-Apr-2020 | Cancelled | Clinical Trials - Phase 2 | |||
| 7. Later Stage VC (Series 1) | 26-Dec-2019 | Completed | Clinical Trials - Phase 2 | |||
| 6. Debt - General | 29-Mar-2019 | Completed | Clinical Trials - Phase 2 | |||
| 5. Later Stage VC (Series D) | 02-Feb-2017 | Completed | Clinical Trials - Phase 2 | |||
| 4. Later Stage VC (Series C) | 01-Dec-2016 | $25.5M | $50.3M | Completed | Clinical Trials - Phase 2 | |
| 3. Early Stage VC (Series B1) | 11-Mar-2014 | $1000K | $24.8M | Completed | Clinical Trials - Phase 2 |
Tarveda Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series 2 | ||||||||
| Series CS | ||||||||
| Series 1 | ||||||||
| Series DD | ||||||||
| Series CC | ||||||||
| Series BB | 1,443,330 | $0.000100 | $0.12 | $2.04 | $2.04 | 1x | $2.04 | 0.66% |
| Series AA | 189,499 | $0.000100 | $0.09 | $1.58 | $1.58 | 1x | $1.58 | 0.09% |
Tarveda Therapeutics Comparisons
Industry
Financing
Details
Tarveda Therapeutics Competitors (22)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Hemera Biosciences | Formerly VC-backed | Waltham, MA | ||||
| ONL Therapeutics | Venture Capital-Backed | Ann Arbor, MI | ||||
| Agenus | Formerly VC-backed | Lexington, MA | ||||
| Seagen | Formerly VC-backed | Bothell, WA | ||||
| Ultragenyx Pharmaceutical | Formerly VC-backed | Novato, CA |
Tarveda Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Tarveda Therapeutics Patents
Tarveda Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2022540317-A | Hsp90 binding conjugates and their combination therapy | Pending | 25-Jun-2019 | ||
| JP-2022527821-A | Hsp90 binding conjugate and its preparation | Pending | 03-Apr-2019 | ||
| JP-2021525766-A | Combination therapy | Pending | 01-Jun-2018 | ||
| JP-2021521107-A | Pharmaceutical composition with reduced tert-butanol levels | Pending | 05-Apr-2018 | ||
| JP-2021521106-A | Hsp90 targeted conjugate and its formulation | Active | 05-Apr-2018 | A61K31/496 |
Tarveda Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Tarveda Therapeutics FAQs
-
When was Tarveda Therapeutics founded?
Tarveda Therapeutics was founded in 2011.
-
Who is the founder of Tarveda Therapeutics?
Omid Farokhzad MD, Robert Langer Ph.D, and Stephen Lippard Ph.D are the founders of Tarveda Therapeutics.
-
Where is Tarveda Therapeutics headquartered?
Tarveda Therapeutics is headquartered in Watertown, MA.
-
What is the size of Tarveda Therapeutics?
Tarveda Therapeutics has 6 total employees.
-
What industry is Tarveda Therapeutics in?
Tarveda Therapeutics’s primary industry is Drug Discovery.
-
Is Tarveda Therapeutics a private or public company?
Tarveda Therapeutics is a Private company.
-
What is Tarveda Therapeutics’s current revenue?
The current revenue for Tarveda Therapeutics is .
-
How much funding has Tarveda Therapeutics raised over time?
Tarveda Therapeutics has raised $130M.
-
Who are Tarveda Therapeutics’s competitors?
Hemera Biosciences, ONL Therapeutics, Agenus, Seagen, and Ultragenyx Pharmaceutical are some of the 22 competitors of Tarveda Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
